Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Persistence of Inflammation and Study of T2 Pathways Following Inhibition of InterLeukin-5 With Mepolizumab in Severe Eosinophilic Asthma

NCT03610685 is registered in ClinicalTrials.gov with NHS Greater Glasgow and Clyde as lead sponsor.

NCT NCT03610685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03610685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Persistence of Inflammation and Study of T2 Pathways Following Inhibition of InterLeukin-5 With Mepolizumab in Severe Eosinophilic Asthma
Lead sponsor
NHS Greater Glasgow and Clyde
Phase
Phase 4
Overall status
Completed
Start date
October 19, 2018
Completion date
January 7, 2020
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma